FDA Clearance Tracker · K190807
VITROS XT Chemistry Products TBIL-ALKP Slides
Last checked: Nov 19, 2026Latest source record: Apr 26, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Apr 26, 2019
Substantially Equivalent
Time to decision
28 days
Received Mar 29, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K190807
- Device name
- VITROS XT Chemistry Products TBIL-ALKP Slides
- Applicant
- Ortho-Clinical Diagnostics, Inc.
- Applicant location
- Rochester, NY
- Received
- Mar 29, 2019
- Decided
- Apr 26, 2019
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Diazo Colorimetry, Bilirubin (CIG)
- Device class
- Class II
- Regulation
- 21 CFR 862.1110
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code CIG. The earliest in FDA's data is K760479, decided Oct 29, 1976.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K190807
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Ortho-Clinical Diagnostics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K254262 · Decided Sep 4, 2026 · 248 days after receipt
Device type: Devices Detecting Influenza A, B, And C Virus Antigens (PSZ) · Laboratory Medicine & Pathology
K254264 · Decided Sep 4, 2026 · 248 days after receipt
Device type: Simple Point-Of-Care Device To Directly Detect Sars-Cov-2 Viral Targets From Clinical Specimens In Near-Patient Settings (QVF) · Laboratory Medicine & Pathology
K254295 · Decided Jul 10, 2026 · 191 days after receipt
Device type: Reagent, Borrelia Serological Reagent (LSR) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.